ClinicalTrials.gg
CompletedNCT01991990Updated Nov 11, 2015Results posted

A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers

A Phase 4 interventional study of placebo and tocilizumab [RoActemra/Actemra] in Healthy Volunteer, sponsored by Hoffmann-La Roche. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-11-11.

Sponsored by Hoffmann-La Roche · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

This Phase IV, single-blind , randomized, two-arm study will explore the pharmacodynamics effects of RoActemra/Actemra (tocilizumab) on neutrophil redistribution, function and survival in healthy subjects. Subjects will receive either a single dose of intravenous (IV) RoActemra/Actemra at a dose of 8 mg/kg over one hour on study Day 0 or placebo. Neutrophil kinetics data will be collected for all subjects up to Day 10 of the study. Following the last study visit on Day 10, all subjects will attend two further safety follow-up visits on Day 28 and Day 56.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male aged between 18 and 65 years inclusive
  • Healthy as determined by screening assessments
  • (BMI) 18 to 30 kg/m2 inclusive
  • Non-smoker
  • Must agree to use a barrier method of supplemented with spermicide during the treatment period and for at least 150 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  • Participation in a clinical study with an drug within 3 months or at least 5 half-lives (whichever is longer) prior to dosing
  • Current or past history of smoking within 6 months
  • Previous exposure to therapeutic monoclonal antibodies in the past 6 months prior to screening
  • Current or history of any condition that, in the opinion of the investigator, would: place the subject at undue risk; invalidate the giving of ; interfere with PK or PD data; or interfere with the ability of the subject to complete the study
  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
  • Any recurrent infections; infection requiring antibiotic treatment in the 6 weeks prior to dosing; mononucleosis in the 6 months prior to dosing; known , , or ; or active infection at the time of screening
  • Active tuberculosis (TB) requiring treatment within the previous 3 years.
  • Evidence of active malignant disease, diagnosed within the previous 10 years (except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 20 years
  • Primary or secondary immunodeficiency
  • disease
  • Use or dependence on substance of abuse
  • Alcohol abuse or average weekly intake greater than 2 units per day
  • Screening or baseline resting heart rate \< 45 or >90 beats per minute
  • Major surgery within 8 weeks prior to screening
  • Major illness in the 3 months prior to dosing
  • Biliary obstruction
  • Current or past history of diverticulitis
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
18 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: placebo

  • Experimental
    RoActemra/Actemra

    Drug: tocilizumab [RoActemra/Actemra]

Interventions

  • Drugplacebo

    Single i.v. infusion

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    Single 8 mg/kg i.v. infusion

06

What researchers measure

Primary outcomes

  1. Neutrophil Redistribution Analysis on Day 4 (Neutrophil Nadir)

    On Day 4 participants had neutrophils isolated from 100 milliliters (mL) of acid-citrate dextrose (ACD)-anti-coagulated autologous venous blood and labeled in autologous plasma with up to 2.5 megaBecquerel (MBq) 111 Indium (111In)-tropolonate before being reinjected. Participants rested for 45 minutes (min) post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils on Day 4 (45 min post re-injection) in the blood, liver/spleen and pelvic bone marrow, expressed as percentages of total body counts (TBCs).

    Time frame: Day 4

  2. Neutrophil Redistribution Analysis on Day 5

    On Day 4 participants had neutrophils isolated from 100 mL of ACD-anti-coagulated autologous venous blood and labeled with up to 2.5 MBq 111In-tropolonate before being reinjected. Participants rested for 45 min post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils and peak counts, on Day 5 (24-hours post re-injection) in liver/spleen and pelvic bone marrow were decay corrected and expressed as percentages of Day 4 (45 minutes post re-injection).

    Time frame: Day 5

  3. Neutrophil Redistribution Analysis on Day 10

    On Day 4 participants had neutrophils isolated from 100 mL of ACD-anti-coagulated autologous venous blood and labeled with up to 2.5 MBq 111In-tropolonate before being reinjected. Participants rested for 45 min post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils and peak counts, on Day 10 (6 days post re-injection) in liver/spleen and pelvic bone marrow were decay corrected and expressed as percentages of Day 4 (45 minutes post re-injection).

    Time frame: Day 10

  4. Neutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in the Percentage of eFluor670-Positive (eFluoro670+) Neutrophils

    Neutrophil phagocytosis was assessed by flow cytometry using heat-killed Staphylococcal pneumonia (S.pneumonia) bacteria labeled with eFluor670. Phagocytosis was quantified by measuring the eFluor670 fluorescence from neutrophils containing phagocytosed bacteria. Experiments were performed using neutrophils (PMN) only, PMN plus S. pneumonia at 4 degrees(˚) centigrade (C) (to control for non-specific bacterial adherence to PMN cell surface), and PMN plus S. pneumonia at 37˚C. Change from baseline in the percentage of eFluor670+ neutrophils was calculated on Day 4.

    Time frame: Baseline, Day 4

  5. Neutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in Median Fluorescence Intensity (MFI) of eFluor670+ Neutrophils

    Neutrophil phagocytosis was assessed by flow cytometry using heat-killed Staphylococcal pneumonia bacteria labeled with eFluor670. Phagocytosis was quantified by measuring the eFluor670 fluorescence from neutrophils containing phagocytosed bacteria. Experiments were performed using neutrophils (PMN) only, PMN plus S. pneumonia at 4˚C (to control for non-specific bacterial adherence to PMN cell surface), and PMN plus S. pneumonia at 37˚C. Change from baseline in the eFluor670+ MFI was calculated on Day 4.

    Time frame: Baseline, Day 4

  6. Neutrophil Respiratory Burst: Change From Baseline to Nadir (Day 4) in the Production of Reactive Oxygen Species as Measured by Chemiluminescence (Relative Light Units - Absolute)

    Neutrophils generate a respiratory burst using reactive oxygen species (ROS) to kill invading pathogens. When luminol is used as a substrate for ROS, a chemical reaction is produced resulting in photon emission (chemiluminescence) in primed and unprimed neutrophils following formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation which is quantifiable. fMLP stimulation of the respiratory burst is mediated through activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in primed neutrophils. The maximal fMLP response is observed in primed neutrophils and is an ex vivo measure of the capacity of neutrophils to respond to pathogenic stimuli. In the current experiments, neutrophils were primed with tumor necrosis factor alpha (TNFα). Light emission was recorded on a luminometer. Absolute change from baseline in the production of ROS on Day 4 was reported.

    Time frame: Baseline, Day 4

  7. Neutrophil Survival: Change From Baseline to the Nadir (Day 4) in the Percentage of Apoptotic Neutrophils as Measured by Microscopic Morphology

    Neutrophil apoptosis was measured using microscopy method with slides stained with Diff-Quik (modified Wright Giemsa stain) and morphology examined under oil immersion light microscopy with 100 times magnification. Neutrophils constitutively undergo apoptosis when cultured ex vivo, and this can be delayed by the addition of agents such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or TNFα. Apoptotic neutrophils were characterized with dark and pyknotic nuclei compared to the viable neutrophils. Change from baseline in the percentage of apoptotic neutrophils on Day 4 measured by microscopy is reported.

    Time frame: Baseline, Day 4

  8. Neutrophil Survival: Change From Baseline to the Nadir in the Percentage of Apoptotic Neutrophils as Measured by Flow Cytometry

    Ageing neutrophils translocate phosphatidylserine from the inner leaflet of the plasma membrane to the outer leaflet during the early stages of apoptosis. This translocation can be measured due to the affinity of Annexin V (AV) to bind exposed phosphatidylserine. Propidium Iodide (PI) is normally membrane-impermeable but enters cells in late apoptosis when their plasma membrane becomes leaky. Neutrophils constitutively undergo apoptosis when cultured ex vivo, and this can be delayed by the addition of agents such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or TNFα. Apoptosis was assessed by flow cytometry with fluorescein isocyanate-labeled recombinant human AV (AV-FITC) and PI staining and the change from baseline in the percentage of apoptotic neutrophils on Day 4 measured by flow cytometry is reported.

    Time frame: Baseline, Day 4

  9. Neutrophil Morphology: Change From Baseline to Nadir in the Number of Neutrophils With Shape Change Measured Using Flow Cytometry

    Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), phosphate-buffered saline (PBS) control (30 min control) and formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ milliliter \[mL\]) were fixed with CellFIX (organic solvent used as fixative for adherent cells), 90 microliters (μL) transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by measuring forward scatter (FSC) on flow cytometry. Change from baseline in the number of neutrophils with shape change on Day 4 was reported.

    Time frame: Baseline, Day 4

  10. Neutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Flow Cytometry (FSC-High Cells)

    Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), PBS control (30 min control) and fMLP-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ mL) were fixed with CellFIX, 90 μL transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by measuring FSC on flow cytometry. Change from baseline in the percentage of neutrophils with shape change on Day 4 was reported.

    Time frame: Baseline, Day 4

  11. Neutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Microscopic Morphology

    Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), PBS control (30 min control) and fMLP-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ mL) were fixed with CellFIX, 90 μL transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by microscopy with neutrophils classified as shape-changed if they contained \> 1 cell surface bleb or irregularity and change from baseline in percentage of neutrophil with shape change on Day 4 was reported.

    Time frame: Baseline, Day 4

  12. Absolute Median Fluorescence Intensities of Neutrophil Adhesion Molecules

    Neutrophil surface receptor expression may be used to characterize the activation status of neutrophils. Fresh (0 min), PBS control (30 min) and fMLP-stimulated (30 min) PMNs (5 × 10\^6 PMNs/mL) were fixed with CellFIX, and 90 μL transferred to each tube containing antibody mixture (2 μL cluster of differentiation \[CD\] 11b-brilliant violet (BV) 421, 2 μL CD16-FITC, 5 μL CD62L-allophycocyanin (APC) and 5 μL CD162-phycoerythrin \[PE\]) or isotype control mixture of equivalent volumes. After 30 minutes of incubation on ice and in the dark, cold PBS was added to stop further reaction. Surface marker expressions were quantified by flow cytometry.

    Time frame: Day 4

07

Results

Posted Nov 11, 2015

Participant flow

Participant flow — Overall Study
MilestonePlaceboTocilizumab
Started612
Completed612
Not completed00

Outcome measures

PrimaryNeutrophil Redistribution Analysis on Day 4 (Neutrophil Nadir)

On Day 4 participants had neutrophils isolated from 100 milliliters (mL) of acid-citrate dextrose (ACD)-anti-coagulated autologous venous blood and labeled in autologous plasma with up to 2.5 megaBecquerel (MBq) 111 Indium (111In)-tropolonate before being reinjected. Participants rested for 45 minutes (min) post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils on Day 4 (45 min post re-injection) in the blood, liver/spleen and pelvic bone marrow, expressed as percentages of total body counts (TBCs).

Time frame:
Day 4
Reported as:
Mean · percentage of total body count
Neutrophil Redistribution Analysis on Day 4 (Neutrophil Nadir)
percentage of total body countPlaceboTocilizumab (Polymorphonuclear Leukocyte (PMN)]-High Group)Tocilizumab (PMN-Low Group)
Blood26.7 ± 4.726.5 ± 1.930.8 ± 5
Liver/Spleen50.4 ± 1.655 ± 3.152.4 ± 1.1
Pelvic marrow12.6 ± 0.911.7 ± 110.8 ± 1
PrimaryNeutrophil Redistribution Analysis on Day 5

On Day 4 participants had neutrophils isolated from 100 mL of ACD-anti-coagulated autologous venous blood and labeled with up to 2.5 MBq 111In-tropolonate before being reinjected. Participants rested for 45 min post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils and peak counts, on Day 5 (24-hours post re-injection) in liver/spleen and pelvic bone marrow were decay corrected and expressed as percentages of Day 4 (45 minutes post re-injection).

Time frame:
Day 5
Reported as:
Mean · percentage of Day 4 counts
Neutrophil Redistribution Analysis on Day 5
percentage of Day 4 countsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
Liver/spleen peak counts (Day 5)91.0 ± 5.190.3 ± 5.0105.2 ± 3.3
Pelvic peak counts (Day 5)187.8 ± 14.1178.4 ± 18.9129.1 ± 7.0
PrimaryNeutrophil Redistribution Analysis on Day 10

On Day 4 participants had neutrophils isolated from 100 mL of ACD-anti-coagulated autologous venous blood and labeled with up to 2.5 MBq 111In-tropolonate before being reinjected. Participants rested for 45 min post-injection to allow for neutrophil equilibrium between the circulating and marginating neutrophil pools. Whole-body profiling was performed in a heavily shielded dedicated whole-body counter with 2 highly sensitive scintillation detectors with the recorded counts corrected for the physical decay of 111In to allow measurement of the effect of TCZ on the normal redistribution pattern of neutrophils and assessment of margination of neutrophils in the presence of TCZ. Distribution of radiolabelled neutrophils and peak counts, on Day 10 (6 days post re-injection) in liver/spleen and pelvic bone marrow were decay corrected and expressed as percentages of Day 4 (45 minutes post re-injection).

Time frame:
Day 10
Reported as:
Mean · percentage of Day 4 counts
Neutrophil Redistribution Analysis on Day 10
percentage of Day 4 countsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
Liver/spleen peak counts (Day 10)84.1 ± 6.276.6 ± 3.396.2 ± 2.9
Pelvic peak counts (Day 10)180.3 ± 12.9175.6 ± 14.4132.6 ± 5.0
PrimaryNeutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in the Percentage of eFluor670-Positive (eFluoro670+) Neutrophils

Neutrophil phagocytosis was assessed by flow cytometry using heat-killed Staphylococcal pneumonia (S.pneumonia) bacteria labeled with eFluor670. Phagocytosis was quantified by measuring the eFluor670 fluorescence from neutrophils containing phagocytosed bacteria. Experiments were performed using neutrophils (PMN) only, PMN plus S. pneumonia at 4 degrees(˚) centigrade (C) (to control for non-specific bacterial adherence to PMN cell surface), and PMN plus S. pneumonia at 37˚C. Change from baseline in the percentage of eFluor670+ neutrophils was calculated on Day 4.

Time frame:
Baseline, Day 4
Reported as:
Mean · percentage of eFlouro+ neutrophils
Neutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in the Percentage of eFluor670-Positive (eFluoro670+) Neutrophils
percentage of eFlouro+ neutrophilsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
PMN only0 ± 00 ± 00 ± 0
PMN and S.pneumonia at 4˚C-1 ± 12 ± 15 ± 2
PMN and S.pneumonia at 37˚C4 ± 27.5 ± 29 ± 2
PrimaryNeutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in Median Fluorescence Intensity (MFI) of eFluor670+ Neutrophils

Neutrophil phagocytosis was assessed by flow cytometry using heat-killed Staphylococcal pneumonia bacteria labeled with eFluor670. Phagocytosis was quantified by measuring the eFluor670 fluorescence from neutrophils containing phagocytosed bacteria. Experiments were performed using neutrophils (PMN) only, PMN plus S. pneumonia at 4˚C (to control for non-specific bacterial adherence to PMN cell surface), and PMN plus S. pneumonia at 37˚C. Change from baseline in the eFluor670+ MFI was calculated on Day 4.

Time frame:
Baseline, Day 4
Reported as:
Mean · median fluoresence intensity
Neutrophil Phagocytosis: Change From Baseline to Nadir (Day 4) in Median Fluorescence Intensity (MFI) of eFluor670+ Neutrophils
median fluoresence intensityPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
PMN only-1 ± 32 ± 72 ± 2
PMN and S.pneumonia at 4˚C-2 ± 339 ± 1832 ± 7
PMN and S.pneumonia at 37˚C685 ± 443979 ± 350810 ± 217
PrimaryNeutrophil Respiratory Burst: Change From Baseline to Nadir (Day 4) in the Production of Reactive Oxygen Species as Measured by Chemiluminescence (Relative Light Units - Absolute)

Neutrophils generate a respiratory burst using reactive oxygen species (ROS) to kill invading pathogens. When luminol is used as a substrate for ROS, a chemical reaction is produced resulting in photon emission (chemiluminescence) in primed and unprimed neutrophils following formyl-methionyl-leucyl-phenylalanine (fMLP) stimulation which is quantifiable. fMLP stimulation of the respiratory burst is mediated through activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in primed neutrophils. The maximal fMLP response is observed in primed neutrophils and is an ex vivo measure of the capacity of neutrophils to respond to pathogenic stimuli. In the current experiments, neutrophils were primed with tumor necrosis factor alpha (TNFα). Light emission was recorded on a luminometer. Absolute change from baseline in the production of ROS on Day 4 was reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · relative light units
Neutrophil Respiratory Burst: Change From Baseline to Nadir (Day 4) in the Production of Reactive Oxygen Species as Measured by Chemiluminescence (Relative Light Units - Absolute)
relative light unitsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
Unprimed neutrophils-16710 ± 12346-5553 ± 6409-2766 ± 3291
TNF α primed neutrophils82465 ± 16727-45257 ± 1754064072 ± 16130
PrimaryNeutrophil Survival: Change From Baseline to the Nadir (Day 4) in the Percentage of Apoptotic Neutrophils as Measured by Microscopic Morphology

Neutrophil apoptosis was measured using microscopy method with slides stained with Diff-Quik (modified Wright Giemsa stain) and morphology examined under oil immersion light microscopy with 100 times magnification. Neutrophils constitutively undergo apoptosis when cultured ex vivo, and this can be delayed by the addition of agents such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or TNFα. Apoptotic neutrophils were characterized with dark and pyknotic nuclei compared to the viable neutrophils. Change from baseline in the percentage of apoptotic neutrophils on Day 4 measured by microscopy is reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · percentage of apoptotic neutrophils
Neutrophil Survival: Change From Baseline to the Nadir (Day 4) in the Percentage of Apoptotic Neutrophils as Measured by Microscopic Morphology
percentage of apoptotic neutrophilsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
Untreated neutrophils-6.0 ± 3.0-1.8 ± 4.0-6.0 ± 5.0
GM-CSF neutrophils-1.0 ± 1.0-7.0 ± 5.0-12.0 ± 6.0
TNFα neutrophils-2.0 ± 4.03.0 ± 4.0-4.0 ± 5.0
PrimaryNeutrophil Survival: Change From Baseline to the Nadir in the Percentage of Apoptotic Neutrophils as Measured by Flow Cytometry

Ageing neutrophils translocate phosphatidylserine from the inner leaflet of the plasma membrane to the outer leaflet during the early stages of apoptosis. This translocation can be measured due to the affinity of Annexin V (AV) to bind exposed phosphatidylserine. Propidium Iodide (PI) is normally membrane-impermeable but enters cells in late apoptosis when their plasma membrane becomes leaky. Neutrophils constitutively undergo apoptosis when cultured ex vivo, and this can be delayed by the addition of agents such as granulocyte-macrophage colony-stimulating factor (GM-CSF) or TNFα. Apoptosis was assessed by flow cytometry with fluorescein isocyanate-labeled recombinant human AV (AV-FITC) and PI staining and the change from baseline in the percentage of apoptotic neutrophils on Day 4 measured by flow cytometry is reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · percentage of apoptotic neutrophils
Neutrophil Survival: Change From Baseline to the Nadir in the Percentage of Apoptotic Neutrophils as Measured by Flow Cytometry
percentage of apoptotic neutrophilsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
Untreated neutrophils-5.0 ± 2.0-8.0 ± 4.0-7.0 ± 5.0
GM-CSF neutrophils-4.0 ± 2.0-13.0 ± 4.0-9.0 ± 8.0
TNFα neutrophils-3.0 ± 4.03.0 ± 2.03.0 ± 5.0
PrimaryNeutrophil Morphology: Change From Baseline to Nadir in the Number of Neutrophils With Shape Change Measured Using Flow Cytometry

Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), phosphate-buffered saline (PBS) control (30 min control) and formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ milliliter \[mL\]) were fixed with CellFIX (organic solvent used as fixative for adherent cells), 90 microliters (μL) transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by measuring forward scatter (FSC) on flow cytometry. Change from baseline in the number of neutrophils with shape change on Day 4 was reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · neutrophils with shape change
Neutrophil Morphology: Change From Baseline to Nadir in the Number of Neutrophils With Shape Change Measured Using Flow Cytometry
neutrophils with shape changePlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
0 min control1613 ± 842-359 ± 26134790 ± 1341
30 min control4882 ± 3069-2309 ± 44398814 ± 3016
30 min fMLP-1889 ± 2800-1667 ± 40931524 ± 3515
PrimaryNeutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Flow Cytometry (FSC-High Cells)

Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), PBS control (30 min control) and fMLP-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ mL) were fixed with CellFIX, 90 μL transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by measuring FSC on flow cytometry. Change from baseline in the percentage of neutrophils with shape change on Day 4 was reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · percentage of shape changed neutrophils
Neutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Flow Cytometry (FSC-High Cells)
percentage of shape changed neutrophilsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
0 min control14.0 ± 11.00.0 ± 3.02.0 ± 2.0
30 min control17.0 ± 8.01.0 ± 4.06.0 ± 3.0
30 min fMLP1.0 ± 3.00.0 ± 2.0-1.0 ± 3.0
PrimaryNeutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Microscopic Morphology

Neutrophil shape change is an indicator of the chemotactic ability of neutrophils to respond to and migrate to sites of inflammation. For determination of neutrophil shape change, fresh (0 min control), PBS control (30 min control) and fMLP-stimulated (30 min fMLP) PMNs (at 5 × 10\^6 PMNs/ mL) were fixed with CellFIX, 90 μL transferred to each sample tube, and cold PBS added to stop further reaction. Shape change was assessed by microscopy with neutrophils classified as shape-changed if they contained \> 1 cell surface bleb or irregularity and change from baseline in percentage of neutrophil with shape change on Day 4 was reported.

Time frame:
Baseline, Day 4
Reported as:
Mean · percentage of shape changed neutrophils
Neutrophil Morphology: Change From Baseline to the Nadir (Day 4) in the Percentage of Neutrophils With Shape Change Measured by Microscopic Morphology
percentage of shape changed neutrophilsPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
0 min control12.0 ± 10.0-3.0 ± 4.00.0 ± 2.0
30 min control13.0 ± 11.0-2.0 ± 4.0-1.0 ± 1.0
30 min fMLP2.0 ± 6.04.0 ± 5.0-1.0 ± 3.0
PrimaryAbsolute Median Fluorescence Intensities of Neutrophil Adhesion Molecules

Neutrophil surface receptor expression may be used to characterize the activation status of neutrophils. Fresh (0 min), PBS control (30 min) and fMLP-stimulated (30 min) PMNs (5 × 10\^6 PMNs/mL) were fixed with CellFIX, and 90 μL transferred to each tube containing antibody mixture (2 μL cluster of differentiation \[CD\] 11b-brilliant violet (BV) 421, 2 μL CD16-FITC, 5 μL CD62L-allophycocyanin (APC) and 5 μL CD162-phycoerythrin \[PE\]) or isotype control mixture of equivalent volumes. After 30 minutes of incubation on ice and in the dark, cold PBS was added to stop further reaction. Surface marker expressions were quantified by flow cytometry.

Time frame:
Day 4
Reported as:
Mean · median fluoresence intensity
Absolute Median Fluorescence Intensities of Neutrophil Adhesion Molecules
median fluoresence intensityPlaceboTocilizumab (PMN-High Group)Tocilizumab (PMN-Low Group)
CD11b - 0 min control12633 ± 206215751 ± 204317764 ± 1910
CD11b - 30 min control13144 ± 241616047 ± 205818134 ± 1836
CD11b - 30 min fMLP39629 ± 269944481 ± 504941339 ± 2723
CD16 - 0 min control15822 ± 74116872 ± 187415901 ± 1476
CD16 - 30 min control13771 ± 70614885 ± 174413475 ± 1269
CD16 - 30 min fMLP17145 ± 88418229 ± 261314707 ± 2205
CD62L - 0 min control563 ± 37650 ± 201767 ± 65
CD62L - 30 min control493 ± 38588 ± 181615 ± 37
CD62L - 30 min fMLP6 ± 35 ± 99 ± 12
CD162 - 0 min control3393 ± 4543253 ± 8953849 ± 314
CD162 - 30 min control3088 ± 4332972 ± 8203355 ± 347
CD162 - 30 min fMLP1571 ± 2191568 ± 4721733 ± 154

Adverse events

Collected over From baseline to 8 weeks of safety follow-up (approximately 8 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/6 (0%)3/6 (50%)
Tocilizumab—0/12 (0%)5/12 (41.7%)
Most frequent other events
Most frequent other events
EventPlaceboTocilizumab
HeadacheNervous system disorders2/61/12
Aspartate aminotransferase increasedInvestigations0/62/12
Eosinophil count increasedInvestigations1/60/12
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/62/12
Alanine aminotransferase increasedInvestigations0/61/12
Blood bilirubin increasedInvestigations0/61/12
NauseaGastrointestinal disorders0/61/12
Rash erythematousSkin and subcutaneous tissue disorders0/61/12

Baseline characteristics

Includes all the randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboTocilizumabTotal
Mean29.5 ± 11.034.5 ± 12.632.7 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboTocilizumabTotal
Female000
Male61218
08

Study locations

1 site
  • Cambridge, CB2 0QQ, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2015, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2013
First posted
Nov 25, 2013
Start
May 2014
Primary completionActual
Dec 2014
CompletionActual
Dec 2014
Results first posted
Nov 11, 2015
Last update
Nov 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01991990
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 25, 2013
Start date
May 2014
Primary completion
Dec 2014
Completion
Dec 2014
Results posted
Nov 11, 2015
Last update
Nov 11, 2015

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion